Advertisement

Successful intra-class switching among IL-17 antagonists: a multicentre, multinational, retrospective study

  • Irina Gasslitter
  • Natalia Kirsten
  • Matthias Augustin
  • Kaspar Torz
  • Ulrich Mrowietz
  • Kilian Eyerich
  • Lluís Puig
  • Wolfram Hoetzenecker
  • Martina Schütz-Bergmayr
  • Wolfgang Weger
  • Peter Wolf
  • Norbert Reider
  • Gudrun Ratzinger
  • Karolina Papageorgiou
  • Thomas O. Meier
  • Julia-Tatjana Maul
  • Florian Anzengruber
  • Alexander A. NavariniEmail author
Concise Communication

Abstract

IL-17 blockers are among the newer anti-psoriatic treatment options and little is known about the interclass switching. We have thus initiated a multi-center, multi-national, retrospective study to assess the treatment response of patients who were switched from one IL-17 blocker to another. Analysis consisted of data from patients with moderate-to-severe psoriasis who did not respond satisfactorily to one of the available IL-17 blockers (secukinumab, ixekizumab, brodalumab) and were subsequently switched to another drug of this class. After 12 weeks of treatment, patients’ PASIs were evaluated. Treatment success was defined as reaching PASI 75 after 12 weeks. Topical treatment was allowed and used in all patients. 26 patients were included (13 male, 13 female) and 29 switches were evaluated. Overall, 29 switches in 21 patients were evaluated. 18 patients changed their therapy from secukinumab to ixekizumab, or in 7 cases to brodalumab. Brodalumab was used in 3 cases after failure of treatment with ixekizumab. Only in one case, non-response of brodalumab resulted in a therapy switch to secukinumab. In 15 (52%) cases, PASI 75 was reached. In 6 (20%) patients, the switch led to a PASI 50 response. No success of treatment was seen among 8 (28%) participants. When patients fail to respond or do not tolerate an IL-17 blocker, switching to another anti-IL-17A/RA is a promising viable option. Larger studies are needed to confirm our results.

Keywords

Interleukin-17 IL-17 IL-17A IL-17 receptor blocker Secukinumab Ixekizumab Brodalumab 

Notes

References

  1. 1.
    Durham LE, Kirkham BW, Taams LS (2015) Contribution of the IL-17 pathway to psoriasis and psoriatic arthritis. Curr Rheumatol Rep 17(8):55CrossRefGoogle Scholar
  2. 2.
    Krueger JG, Fretzin S, Suarez-Farinas M, Haslett PA, Phipps KM, Cameron GS et al (2012) IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis. J Allergy Clin Immunol 130(1):145 e9–154 e9CrossRefGoogle Scholar
  3. 3.
    Tausend W, Downing C, Tyring S (2014) Systematic review of interleukin-12, interleukin-17, and interleukin-23 pathway inhibitors for the treatment of moderate-to-severe chronic plaque psoriasis: ustekinumab, briakinumab, tildrakizumab, guselkumab, secukinumab, ixekizumab, and brodalumab. J Cutan Med Surg 18(3):156–169CrossRefGoogle Scholar
  4. 4.
    Blauvelt A, Papp KA, Griffiths CEM, Puig L, Weisman J, Dutronc Y et al (2018) Correction to: efficacy and safety of switching to ixekizumab in etanercept non-responders: a subanalysis from two phase III randomized clinical trials in moderate-to-severe plaque psoriasis (UNCOVER-2 and-3). Am J Clin Dermatol 19(3):457CrossRefGoogle Scholar
  5. 5.
    Damiani G, Conic RRZ, de Vita V, Costanzo A, Regazzini R, Pigatto PDM et al (2018) When IL-17 inhibitors fail: real-life evidence to switch from secukinumab to adalimumab or ustekinumab. Dermatol Ther 2018:e12793CrossRefGoogle Scholar
  6. 6.
    Georgakopoulos JR, Phung M, Ighani A, Yeung J (2018) Efficacy and safety of switching to ixekizumab in secukinumab nonresponders with plaque psoriasis: a multicenter retrospective study of interleukin 17A antagonist therapies. J Am Acad Dermatol 79(1):155–157CrossRefGoogle Scholar
  7. 7.
    Mrowietz U, Kragballe K, Reich K, Spuls P, Griffiths CE, Nast A et al (2011) Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res 303(1):1–10CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Irina Gasslitter
    • 1
  • Natalia Kirsten
    • 2
  • Matthias Augustin
    • 2
  • Kaspar Torz
    • 3
  • Ulrich Mrowietz
    • 3
  • Kilian Eyerich
    • 4
  • Lluís Puig
    • 5
  • Wolfram Hoetzenecker
    • 6
  • Martina Schütz-Bergmayr
    • 6
  • Wolfgang Weger
    • 7
  • Peter Wolf
    • 7
  • Norbert Reider
    • 8
  • Gudrun Ratzinger
    • 8
  • Karolina Papageorgiou
    • 9
    • 10
  • Thomas O. Meier
    • 10
  • Julia-Tatjana Maul
    • 9
    • 10
  • Florian Anzengruber
    • 9
    • 10
  • Alexander A. Navarini
    • 9
    • 10
    Email author
  1. 1.Department of Internal Medicine IIUniversity of InnsbruckInnsbruckAustria
  2. 2.German Center for Health Services Research in Dermatology (CVderm), Institute for Health Services Research in Dermatology and Nursing (IVDP)University Medical Center Hamburg-Eppendorf (UKE)HamburgGermany
  3. 3.Psoriasis Center at the Department of DermatologyUniversity Medical CenterKielGermany
  4. 4.Department of Dermatology and Allergy BiedersteinTechnical University of MunichMunichGermany
  5. 5.Dermatology ServiceHospital de la Santa Creu i Sant PauBarcelonaSpain
  6. 6.Department of DermatologyKepler University HospitalLinzAustria
  7. 7.Department of DermatologyMedical University of GrazGrazAustria
  8. 8.Department of DermatologyUniversity of InnsbruckInnsbruckAustria
  9. 9.Department of DermatologyUniversity Hospital ZurichZurichSwitzerland
  10. 10.Faculty of MedicineUniversity of ZurichZurichSwitzerland

Personalised recommendations